Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03345550 · ClinicalTrials.gov registry record · Phase 2
OPTIMA-TBI Pilot Study
A Phase 2 study, sponsored by University of Michigan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT03345550 is a Phase 2 study that was terminated before completion, run by University of Michigan. The registered enrollment target is 44 participants.
The verdict
NCT03345550, a Phase 2 study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a double-blind, randomized controlled trial comparing the effect of omega-3 fatty acid versus placebo on blood biomarkers of brain injury, inflammation and neurogenesis.
Interventions
- DRUG Placebo - Cap
- DRUG Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2017-09-12 |
| Est. Completion | 2021-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03345550
The ClinicalTrials.gov registry entry for NCT03345550 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo - Cap is the first listed.
NCT03345550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03345550 about?
NCT03345550 is a clinical study titled "OPTIMA-TBI Pilot Study". This is a double-blind, randomized controlled trial comparing the effect of omega-3 fatty acid versus placebo on blood biomarkers of brain injury, inflammation and neurogenesis.
What is the current status of trial NCT03345550?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2017-09-12. Estimated completion is 2021-07-27.
What interventions are being tested in trial NCT03345550?
The interventions under investigation include: Placebo - Cap (DRUG), Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules. (DRUG).
Who is sponsoring clinical trial NCT03345550?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.